Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Stopped early · Phase 1
Conditions studied: Intraocular Melanoma, Melanoma (Skin)
In brief
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Vaccine therapy plus filgrastim combined with a specific protein may be a more effective treatment for melanoma. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma that has been completely removed during surgery.
Key facts
- Study ID
- NCT00005841
- Run by
- University of Southern California
- People needed
- 15
- Starts
- 2000-06-01
- Expected to finish
- 2002-10-01
- Last updated by the study team
- 2014-05-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
- City of Hope National Medical Center — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.